Story perspectives

Elevidys: Groundbreaking Gene Therapy for Duchenne Muscular Dystrophy Approved

1/27/2026

50 5

Summary

Story summary

Sarepta Therapeutics released three-year data showing Elevidys delivers sustained motor benefits for Duchenne muscular dystrophy.
In children aged four to seven at treatment, motor function stayed higher than untreated controls, with 73% slower progression.
The FDA expanded the label, making Elevidys the only approved gene therapy for Duchenne muscular dystrophy.
No new safety issues were reported.
Earlier safety concerns included two patient deaths.

1 of 1

Story summary

Sarepta Therapeutics released three-year data showing Elevidys delivers sustained motor benefits for Duchenne muscular dystrophy.
In children aged four to seven at treatment, motor function stayed higher than untreated controls, with 73% slower progression.
The FDA expanded the label, making Elevidys the only approved gene therapy for Duchenne muscular dystrophy.
No new safety issues were reported.
Earlier safety concerns included two patient deaths.